3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Sarcoma
1
Genitourinary
1
Gastrointestinal
1
Breast
1
Conditions
Prostatic Neoplasms
7
Pancreatic Neoplasms
5
Colorectal Neoplasms
5
Melanoma
4
Carcinoma, Non-Small-Cell Lung
4
Carcinoma, Hepatocellular
4
Breast Neoplasms
4
Prostatic Neoplasms, Castration-Resistant
3
Neoplasms
3
Uterine Cervical Neoplasms
2
Triple Negative Breast Neoplasms
2
Squamous Cell Carcinoma of Head and Neck
2
Small Cell Lung Carcinoma
2
Ovarian Neoplasms
2
Neoplasm Metastasis
2
Carcinoma, Renal Cell
2
Urinary Bladder Neoplasms
1
Thrombocytosis
1
Stomach Neoplasms
1
Primary Myelofibrosis
1
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Neoplasms, Squamous Cell
1
Myeloproliferative Disorders
1
Myelodysplastic-Myeloproliferative Diseases
1
Myelodysplastic Syndromes
1
Multiple Myeloma
1
Mesothelioma
1
Lymphoma, Non-Hodgkin
1
Liver Neoplasms
1
Liposarcoma
1
Interventions
pembrolizumab
3
spartalizumab
2
trametinib
1
tislelizumab
1
palbociclib
1
nazartinib
1
milademetan
1
enzalutamide
1
devimistat
1
dehydroftorafur
1
canakinumab
1
binimetinib
1
bemarituzumab
1
aldesleukin
1
Specimen Handling
1
Pentostatin
1
Midazolam
1
Methods
1
Magnetic Resonance Spectroscopy
1
Letrozole
1
Interleukin-2
1
IFL protocol
1
Hydroxychloroquine
1
Gemcitabine
1
Fulvestrant
1
Fluorouracil
1
Early Intervention, Educational
1
Cyclophosphamide
1
Cetuximab
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Adenocarcinoma of Lung
×
enzalutamide
×
Gastrointestinal
×
Clear all
NCT04557449
2025-10-01
CDK4i
Pfizer
Phase 2
Active not recruiting
362 enrolled